This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:hiv_and_aids [02.17.2019] – [AIDS patients on the Marshall Protocol] sallieq | home:diseases:hiv_and_aids [02.17.2019] – [at this time there are no AIDS patients on the Marshall Protocol] sallieq | ||
---|---|---|---|
Line 9: | Line 9: | ||
One of the key mechanisms that HIV fosters immune dysfunction is through completely taking over the VDR and interfering with D-binding protein. As a result, en end-stage AIDS patients levels of 1,25-D approach zero. | One of the key mechanisms that HIV fosters immune dysfunction is through completely taking over the VDR and interfering with D-binding protein. As a result, en end-stage AIDS patients levels of 1,25-D approach zero. | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | ===== Vitamin D metabolism ===== | ||
+ | |||
+ | < | ||
+ | |||
+ | HIV uses the VDR to recognize its own LTR promoter region in order to transcribe its own genome, thus taking over the VDR.(({{pubmed> | ||
+ | |||
+ | {{section>: | ||
+ | |||
+ | There is no evidence that supplemental vitamin D helps HIV or AIDS patients. | ||
+ | |||
+ | < | ||
+ | |||
+ | Of note, we observed that patients with low vitamin D levels displayed a reduced CD4/CD8 ratio (P ¼ 0.03, Table 1), which is usually a sign of increased immune activation in HIV-infected patients receiving effective ART [16]. We also analyzed CD38 expression on the surface of memory CD8+ T cells as a robust marker of immune activation. Although there was substantial interindividual variability, | ||
+ | |||
+ | We thus monitored CD4/CD8 ratio, as well as cellular activation (i.e. CD38 expression) and cell cycling (i.e. Ki67 expression) of memory CD8+ T cells in vitamin D supplemented individuals. These patients presented a higher CD4/CD8 ratio post-compared with pre-supplementation (Fig. 1b). Moreover, vitamin D increase upon supplementation was associated with a reduction in cellular immune activation levels (Fig. 1c). We also found that serum levels of vitamin D and the expression of the cellular immune activation markers were inversely correlated in this longitudinal setting (Fig. 1d). Vitamin D status appears therefore to impact on cellular immune activation levels.</ | ||
+ | |||
+ | |||
+ | |||
+ | ===== HIV allows opportunistic infections to proliferate ===== | ||
+ | |||
+ | < | ||
+ | |||
+ | Pathogens are able spread effectively in an immunocompromised environment. This means it's possible that AIDS patients pick up substantial pathogen loads. It is further possible that it is these Th1 pathogens, which kill patients. Viral co-infections (including Epstein-Barr virus, Human Herpes Virus 6, etc.) are found in all the diseases the Marshall Protocol treats, but the viruses are not believed to bethe proximate cause of disease. | ||
===== CD38 ===== | ===== CD38 ===== | ||
Line 26: | Line 53: | ||
In vitro, macrophages of CD38 KO mice were less efficient in uptake of listeria but still able to kill the bacteria. Dendritic cells also displayed enhanced CD38 expression following infection. However, absence of CD38 did not impair the capacity of mice to prime CD8+ T cells against L. monocytogenes, | In vitro, macrophages of CD38 KO mice were less efficient in uptake of listeria but still able to kill the bacteria. Dendritic cells also displayed enhanced CD38 expression following infection. However, absence of CD38 did not impair the capacity of mice to prime CD8+ T cells against L. monocytogenes, | ||
- | CD38 and immune function: | + | |
+ | |||
+ | ===== At this time there are no AIDS patients on the Marshall Protocol ===== | ||
+ | |||
+ | |||
+ | The ARF has no clinical experience with AIDS patients yet. However, we do believe it due time that ' | ||
+ | |||
+ | We would argue that it would make sense for an AIDS patient to strengthen his or her immune response and that the only way to do this is to kill the Th1 pathogens which dysregulate it. | ||
+ | |||
+ | A therapeutic probe will confirm the potential efficacy of this treatment. | ||
+ | |||
+ | |||
+ | ===== More research into CD38 and immune function | ||
+ | |||
In mice, CD38 was shown to be required for immunity against S. pneumoniae, as its absence rendered mice more susceptible to infection by this pathogen. This increased susceptibility was associated with a diminished neutrophil chemotaxis in response to peptides of bacterial origin. In humans, CD38 was proposed to have a protective role in HIV infection. However, the mechanisms by which this protection is achieved are, at this point, unclear. As CD38 appears to be important in viral infections and is able to modulate immune responses, namely at the level of Th1 cytokine secretion, it is conceivable that it could also play a role in immunity against intracellular pathogens, such as mycobacteria. | In mice, CD38 was shown to be required for immunity against S. pneumoniae, as its absence rendered mice more susceptible to infection by this pathogen. This increased susceptibility was associated with a diminished neutrophil chemotaxis in response to peptides of bacterial origin. In humans, CD38 was proposed to have a protective role in HIV infection. However, the mechanisms by which this protection is achieved are, at this point, unclear. As CD38 appears to be important in viral infections and is able to modulate immune responses, namely at the level of Th1 cytokine secretion, it is conceivable that it could also play a role in immunity against intracellular pathogens, such as mycobacteria. | ||
Line 67: | Line 107: | ||
- | |||
- | |||
- | ===== Vitamin D metabolism ===== | ||
- | |||
- | < | ||
- | |||
- | HIV uses the VDR to recognize its own LTR promoter region in order to transcribe its own genome, thus taking over the VDR.(({{pubmed> | ||
- | |||
- | {{section>: | ||
- | |||
- | There is no evidence that supplemental vitamin D helps HIV or AIDS patients. | ||
- | |||
- | < | ||
- | |||
- | Of note, we observed that patients with low vitamin D levels displayed a reduced CD4/CD8 ratio (P ¼ 0.03, Table 1), which is usually a sign of increased immune activation in HIV-infected patients receiving effective ART [16]. We also analyzed CD38 expression on the surface of memory CD8+ T cells as a robust marker of immune activation. Although there was substantial interindividual variability, | ||
- | |||
- | We thus monitored CD4/CD8 ratio, as well as cellular activation (i.e. CD38 expression) and cell cycling (i.e. Ki67 expression) of memory CD8+ T cells in vitamin D supplemented individuals. These patients presented a higher CD4/CD8 ratio post-compared with pre-supplementation (Fig. 1b). Moreover, vitamin D increase upon supplementation was associated with a reduction in cellular immune activation levels (Fig. 1c). We also found that serum levels of vitamin D and the expression of the cellular immune activation markers were inversely correlated in this longitudinal setting (Fig. 1d). Vitamin D status appears therefore to impact on cellular immune activation levels.</ | ||
- | |||
- | |||
- | |||
- | ===== HIV allows opportunistic infections to proliferate ===== | ||
- | |||
- | < | ||
- | |||
- | Pathogens are able spread effectively in an immunocompromised environment. This means it's possible that AIDS patients pick up substantial pathogen loads. It is further possible that it is these Th1 pathogens, which kill patients. Viral co-infections (including Epstein-Barr virus, Human Herpes Virus 6, etc.) are found in all the diseases the Marshall Protocol treats, but the viruses are not believed to bethe proximate cause of disease. | ||
- | |||
- | |||
- | |||
- | ===== AIDS patients on the Marshall Protocol ===== | ||
- | |||
- | |||
- | The ARF has no clinical experience with AIDS patients yet. However, we do believe it due time that ' | ||
- | |||
- | We would argue that it would make sense for an AIDS patient to strengthen his or her immune response and that the only way to do this is to kill the Th1 pathogens which dysregulate it. | ||
- | |||
- | A therapeutic probe will confirm the potential efficacy of this treatment. | ||